Clinical trials
Completed Dyspnea trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
132 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 3 |
| 2002 | 2 |
| 2003 | 3 |
| 2004 | 2 |
| 2005 | 4 |
| 2006 | 5 |
| 2007 | 4 |
| 2008 | 9 |
| 2009 | 8 |
| 2010 | 6 |
| 2011 | 11 |
| 2012 | 6 |
| 2013 | 7 |
| 2014 | 12 |
| 2015 | 2 |
| 2016 | 8 |
| 2017 | 6 |
| 2018 | 4 |
| 2019 | 2 |
| 2020 | 6 |
| 2021 | 5 |
| 2022 | 3 |
| 2023 | 8 |
| 2024 | 3 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 132 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Dartmouth-Hitchcock Medical Center | 6 |
| M.D. Anderson Cancer Center | 6 |
| Mayo Clinic | 6 |
| Novartis Pharmaceuticals | 6 |
| Amphastar Pharmaceuticals, Inc. | 4 |
| Vapotherm, Inc. | 4 |
| Beth Israel Deaconess Medical Center | 3 |
| Duke University | 3 |
| National Jewish Health | 3 |
| US Department of Veterans Affairs | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Dyspnea | 132 |
| Pulmonary Disease, Chronic Obstructive | 31 |
| Heart Failure | 15 |
| Asthma | 14 |
| Chest Pain | 11 |
| Pain | 8 |
| Pneumonia | 8 |
| Lung Diseases, Interstitial | 7 |
| Syncope | 6 |
| Dizziness | 5 |
Trials
Showing 1 to 25 of 132. Each trial links to its page on Pharma Observatory.
32 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.